Supernus Pharmaceuticals, Inc.
Launch SPN-812 for pediatric ADHD commercially if FDA approves it
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 22 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“If approved by the FDA, the Company is preparing for the commercial launch of SPN-812 for the treatment of ADHD in pediatric patients in the second quarter of 2021.”
What we found
Evidence strength A What the grades mean
The FDA approved Qelbree (SPN-812) for pediatric ADHD on April 2, 2021, and the company launched it in the U.S. in May 2021, within the second quarter.
-
A Supernus Pharmaceuticals, Inc. 10-Q filed 2021-08-06
“In May 2021, we launched Qelbree in the U.S.” ✓ confirmed on the page
-
A Supernus Pharmaceuticals, Inc. 10-K filed 2022-04-13
“On April 2, 2021, the FDA approved Qelbree (viloxazine extended-release capsule) for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, we launched Qelbree in the U.S.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Commercial launch of SPN-812 for pediatric ADHD
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to FDA approval of the NDA
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Supernus Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-SUPN-024189 · Corrections policy